Showing 463 results
-
Media Release /-- Tekamlo combines in a single-pill the only approved direct renin inhibitor, Tekturna, with the widely prescribed calcium channel blocker, amlodipine-- Data showed Tekamlo significantly reduced…
-
Media Release /- Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies- Exploratory analyses showed…
-
Media Release /Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products;…
-
Media Release /- Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line…
-
Media Release /Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed…
-
Media Release /• Data from FREEDOMS study show Gilenya reduced relapses in patients who discontinued another MS therapy due to side effects or inadequate efficacy• Analyses of five clinical studies show Gilenya,…
-
Media Release /- Cosentyx (secukinumab) is the first IL-17A antagonist to complete Phase III studies which demonstrated efficacy and assessed safety in ankylosing spondylitis (AS)(1)- Cosentyx provided improvements…
-
Media Release /New data show that 73% of ankylosing spondylitis (AS) patients taking Cosentyx® (secukinumab) achieved improvement in AS signs and symptoms at four years, with sustained ASAS response rates1 AS is a…
-
Media Release /- Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer…
-
Media Release /- Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept- Superior reductions in central…
